RHHVF - Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial | Benzinga
Poseida Therapeutics Inc (NASDAQ: PSTX) released early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate.
The company is investigating P-BCMA-ALLO1 in partnership with Roche Holdings AG (OTC: RHHBY) for relapsed/refractory multiple myeloma.
Detailed study findings are being featured at the 65th ASH Annual Meeting and Exposition.
At the October 23, 2023, data cut-off, 39 patients were enrolled as an intent-to-treat (ITT) population in the ongoing Phase 1 multicenter, ...